S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(0.10%) $82.89
Gas
(-0.18%) $1.650
Gold
(-0.55%) $2 325.50
Silver
(-0.77%) $27.14
Platinum
(-0.59%) $910.40
USD/EUR
(-0.07%) $0.934
USD/NOK
(0.01%) $10.98
USD/GBP
(-0.01%) $0.802
USD/RUB
(0.00%) $92.32

Realtime updates for Gracell Biotechnologies [GRCL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 2.72%
SELL
0.00%
return 1.94%
Last Updated21 Feb 2024 @ 16:00

0.05% CNY 10.25

BUY 101242 min ago

@ CNY10.28

Issued: 14 Feb 2024 @ 15:48


Return: -0.29%


Previous signal: Feb 14 - 13:13


Previous signal: Sell


Return: -0.48 %

Live Chart Being Loaded With Signals

Commentary (21 Feb 2024 @ 16:00):
Profile picture for Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Today's Volume 6.37M
Average Volume 1.46M
Market Cap 989.87M
EPS CNY0 ( 2024-03-11 )
Next earnings date ( CNY0 ) 2024-05-13
Last Dividend CNY0 ( N/A )
Next Dividend CNY0 ( N/A )
P/E -10.57
ATR14 CNY0.215 (2.10%)

Volume Correlation

Long: 0.31 (neutral)
Short: 0.24 (neutral)
Signal:(68.183) Neutral

Gracell Biotechnologies Correlation

10 Most Positive Correlations
ENPH0.931
BLU0.927
ATAI0.922
NNOX0.916
PTPI0.915
RDHL0.915
RXT0.915
IMCC0.91
PAVM0.908
VORB0.905
10 Most Negative Correlations
ITMR-0.929
OPNT-0.929
AVEO-0.925
VLYPP-0.923
DVCR-0.923
CIH-0.918
BKCH-0.916
FRGI-0.915
EWEB-0.907
MLCO-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gracell Biotechnologies Correlation - Currency/Commodity

The country flag -0.80
( moderate negative )
The country flag -0.83
( strong negative )
The country flag 0.62
( weak )
The country flag -0.14
( neutral )
The country flag -0.72
( moderate negative )
The country flag 0.83
( strong )

Gracell Biotechnologies Financials

Annual 2022
Revenue: CNY0
Gross Profit: CNY0 (0.00 %)
EPS: CNY-5.65
Q3 2023
Revenue: CNY0
Gross Profit: CNY0 (0.00 %)
EPS: CNY-0.810
Q2 2023
Revenue: CNY0
Gross Profit: CNY0 (0.00 %)
EPS: CNY-2.15
Q1 2023
Revenue: CNY0
Gross Profit: CNY0 (0.00 %)
EPS: CNY-2.24

Financial Reports:

No articles found.

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators